Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report issued to clients and investors on Friday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

Shares of EVOK opened at $2.79 on Friday. Evoke Pharma has a 12-month low of $2.50 and a 12-month high of $12.32. The stock has a market cap of $4.17 million, a P/E ratio of -0.25 and a beta of 0.12. The company has a 50-day moving average of $4.25 and a two-hundred day moving average of $4.63.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings data on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.24). The company had revenue of $3.31 million for the quarter, compared to analyst estimates of $3.08 million. Evoke Pharma had a negative return on equity of 308.49% and a negative net margin of 71.32%.

Institutional Trading of Evoke Pharma

An institutional investor recently raised its position in Evoke Pharma stock. Nantahala Capital Management LLC grew its position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 148,194 shares of the specialty pharmaceutical company’s stock after purchasing an additional 91,945 shares during the period. Nantahala Capital Management LLC owned 9.95% of Evoke Pharma worth $655,000 at the end of the most recent quarter.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.